KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $3.9 million.

  • Pacira BioSciences' Capital Expenditures fell 542.52% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year increase of 6705.12%. This contributed to the annual value of $10.6 million for FY2024, which is 2984.63% down from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Capital Expenditures is $3.9 million, which was down 542.52% from $2.7 million recorded in Q2 2025.
  • Pacira BioSciences' Capital Expenditures' 5-year high stood at $13.1 million during Q3 2021, with a 5-year trough of $1.6 million in Q2 2024.
  • In the last 5 years, Pacira BioSciences' Capital Expenditures had a median value of $5.2 million in 2022 and averaged $6.2 million.
  • As far as peak fluctuations go, Pacira BioSciences' Capital Expenditures tumbled by 7099.28% in 2023, and later skyrocketed by 20141.04% in 2025.
  • Quarter analysis of 5 years shows Pacira BioSciences' Capital Expenditures stood at $9.2 million in 2021, then plummeted by 40.08% to $5.5 million in 2022, then plummeted by 67.26% to $1.8 million in 2023, then grew by 17.8% to $2.1 million in 2024, then surged by 82.72% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $2.7 million for Q2 2025, and $8.5 million during Q1 2025.